Mar 28, 2024 4:01pm EDT SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
Jan 29, 2024 5:15pm EST SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
Jan 05, 2024 8:30am EST SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
Nov 13, 2023 5:17pm EST SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Oct 24, 2023 8:00am EDT SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
Oct 16, 2023 8:00am EDT SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
Sep 27, 2023 8:31pm EDT SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
Aug 14, 2023 4:30pm EDT SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
